MiMedx Group, Inc. (MDXG)

NASDAQ • Healthcare

$3.91

-$0.02 (-0.5%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$3.9

Day Range$3.85 - $3.93

Avg. Volume (3M)1.3M

Market Cap$569.9M

P/E Ratio97.8

52 Week Range

$3.03$7.97

Next EarningsIn 3 daysOct 28, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$64.3M100%

Gross Profitminus cost of goods$44.3M69%

In plain terms: out of every $100 in revenue, MiMedx Group, Inc. currently loses $23.

Fundamentals & Financials

Revenue (TTM)

$355.1M

Net Income (TTM)

$6.2M

EPS (TTM)

$0.04

ROA (TTM)

2.22%

Current Ratio

5.33

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+66.7%Q3 2025$0.1

+114.3%Q4 2025$0.15

+55.6%Q1 2026$0.14

+28.6%Q2 2026-$0.05

-1.0%Q3 2026-$0.05

Oct 28

in 3 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -1.0%

MiMedx’s revenue topped consensus despite a sharp year-over-year decline, based on preliminary results for the second fiscal quarter of 2026 that were reported July 29, 2026. Revenue fell 34.7% to about $64.4 million (down from $98.6 million a year ago), yet still topped expectations, coming in at $64.4 million versus the $63.5 million estimate (+1.4%). Gross profit was roughly $44.4 million, with gross margin at 69.0%. The company generated negative operating cash flow of about $10.0 million during the quarter, and it repurchased roughly $12.6 million of stock. Next-period consensus calls for EPS of -$0.01 on revenue of $69.6 million.

Next report — what to expect

MiMedx Group, Inc. (MDXG) reports on November 4, 2026. Wall Street expects EPS of $0.007 on revenue of $69.6 million. For trailing context, revenue was -34.7% year over year last quarter. MDXG has beaten EPS in 5 of 8 most recent quarters, making the EPS print a key item to watch.

View full earnings history

About MiMedx Group, Inc.

MiMedx Group, Inc. develops and markets placental tissue allografts for wound care, surgical recovery, burn treatment, and related uses in the U.S. healthcare and biotechnology fields. Listed on NASDAQ as MDXG, the company recorded $418.6 million in revenue in FY2025.

Name

MiMedx Group, Inc.

CEO

Joseph H. Capper

Website

www.mimedx.com

Industry

Healthcare

Employees

808

Today's Snapshot

AI-generated

MDXG closed 0.5% below yesterday's close, in line with a weaker sector. MDXG reports earnings on 28 October.

Trading Volume

Below 10d avg (1.7M)

1.2M

vs S&P 500 Today

Inline with Market

+0.01%

Updated: October 23, 2026 at 20:19 UTC

Technical Indicators

1 Buy1 Neutral6 Sell

MDXG is showing a clear downside bias: the stock trades below its short, medium and long moving averages and sits close to the lower Bollinger band and the pivot, while momentum indicators such as MACD and CCI are negative and RSI is near oversold territory. ATR is elevated percentage‑wise, implying meaningful intraday volatility, and OBV is substantially negative, signaling distribution. ADX is moderate, so the downward move has some traction. Technical takeaway: the technical picture supports a strong sell bias with sustained downside pressure.

All signals

EMA (5 indicators)$4.23 - $4.79
Sell
RSI (14)30.48
Neutral
Stochastic %K (14, 3, 3)14.06
Buy
MACD Level (12, 26)-0.16
Sell

Peers & Related Assets

RCELAvita Medical Inc.

$15.51+0.6%

ORGOOrganogenesis Holdings Inc.

$0.99-3.6%

SMTISanara MedTech Inc.

LCTXLineage Cell Therapeutics, Inc.

MDWDMediWound Ltd.

CELUCelularity Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.